All | Mode of detection | |||||||
---|---|---|---|---|---|---|---|---|
Screening participants | Unscreened (eligible) | |||||||
Screen-detecteda | Interval-detected | |||||||
6065 | (100%) | 2049 | (33.8%) | 476 | (7.8%) | 3540 | (58.4%) | |
Age at diagnosis | ||||||||
Mean age at diagnosis (SD) | 61.2 | (6.0) | 62.0 | (5.8) | 61.9 | (6.0) | 60.6 | (6.0) |
< 50 years at diagnosis | N/A | (0%) | N/A | (0%) | N/A | (0%) | N/A | (0%) |
50–69 years at diagnosis | 5950 | (98.1%) | 1970 | (96.1%) | 440 | (92.4%) | 3540 | (100%) |
70–79 years at diagnosis | 115 | (1.9%) | 79 | (3.9%) | 36 | (7.6%) | N/A | (0%) |
80 + years at diagnosis | N/A | (0%) | N/A | (0%) | N/A | (0%) | N/A | (0%) |
Stage at diagnosis | ||||||||
No affected lymph nodes/distant metastases | 5015 | (82.7%) | 1807 | (88.2%) | 392 | (82.4%) | 2816 | (79.5%) |
Affected lymph nodes only | 788 | (13.0%) | 206 | (10.1%) | 72 | (15.1%) | 510 | (14.4%) |
Distant metastases | 262 | (4.3%) | 36 | (1.8%) | 12 | (2.5%) | 214 | (6.0%) |
Breast surgeryb | ||||||||
Breast conserving surgery only | 4608 | (76.0%) | 1756 | (85.7%) | 348 | (73.1%) | 2504 | (70.7%) |
Mastectomy | 1457 | (24.0%) | 293 | (14.3%) | 128 | (26.9%) | 1036 | (29.3%) |
Both types of surgery | 610 | (10.1%) | 151 | (7.4%) | 61 | (12.8%) | 398 | (11.2%) |
Two or more surgeries | 1606 | (26.5%) | 494 | (24.1%) | 145 | (30.5%) | 967 | (27.3%) |
Neoadjuvant systemic therapy | ||||||||
Yes | 501 | (8.3%) | 43 | (2.1%) | 43 | (9.0%) | 415 | (11.7%) |
Adjuvant systemic therapyc | ||||||||
Cytostatic drugs | 2758 | (45.5%) | 771 | (37.6%) | 236 | (49.6%) | 1751 | (49.5%) |
Monoclonal antibody | 57 | (0.9%) | 6 | (0.3%) | 4 | (0.8%) | 47 | (1.3%) |
Hormone therapy | 2823 | (46.5%) | 1086 | (53.0%) | 200 | (42.0%) | 1537 | (43.4%) |
Radiotherapyd | ||||||||
Within ten months after breast surgery | 4866 | (80.2%) | 1708 | (83.4%) | 381 | (80.0%) | 2777 | (78.4%) |
Before breast surgery | 38 | (0.6%) | 3 | (0.1%) | 2 | (0.4%) | 33 | (0.9%) |